Home / Market News / $NAUT
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Roth Capital Partners Analyst Raises Nautilus Biotechnology Price Target

Oct 29, 2026, 1:12 PM UTC · Primary ticker $NAUT

Roth Capital Partners analyst Max Masucci has increased his price target for Nautilus Biotechnology (NAUT) from $3.50 to $4.00, while maintaining a bullish rating. This update reflects the analyst's positive outlook on the company's development of its single-molecule proteomics platform, the Nautilus Voyager, and provides investors with a revised valuation perspective.

Roth Capital Partners analyst Max Masucci has raised the price target for Nautilus Biotechnology (NAUT) from $3.50 to $4.00, while reaffirming a bullish rating. This adjustment signals increased confidence from the analyst in the company's prospects, specifically tied to the ongoing development of its Nautilus Voyager platform for single-molecule proteomics. For traders, this is a moderately positive signal in the short term, as it could attract investor attention and potentially lead to a modest price bump. The long-term implications depend on the successful development and commercialization of the Voyager platform, making the analyst's updated outlook a key opportunity for those bullish on NAUT's technological advancements.

$NAUT positive Analyst price target increase
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.